APA (7th ed.) Citation

Spikes, L. A., Bajwa, A. A., Burger, C. D., Desai, S. V., Eggert, M. S., El‐Kersh, K. A., . . . Shapiro, S. M. (2022). BREEZE: Open‐label clinical study to evaluate the safety and tolerability of treprostinil inhalation powder as Tyvaso DPI™in patients with pulmonary arterial hypertension. Pulmonary Circulation, 12(2), 1. https://doi.org/10.1002/pul2.12063

Chicago Style (17th ed.) Citation

Spikes, Leslie A., et al. "BREEZE: Open‐label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder as Tyvaso DPI™in Patients with Pulmonary Arterial Hypertension." Pulmonary Circulation 12, no. 2 (2022): 1. https://doi.org/10.1002/pul2.12063.

MLA (9th ed.) Citation

Spikes, Leslie A., et al. "BREEZE: Open‐label Clinical Study to Evaluate the Safety and Tolerability of Treprostinil Inhalation Powder as Tyvaso DPI™in Patients with Pulmonary Arterial Hypertension." Pulmonary Circulation, vol. 12, no. 2, 2022, p. 1, https://doi.org/10.1002/pul2.12063.